WO2002036767A3 - Therapeutic oligonucleotides of reduced toxicity - Google Patents

Therapeutic oligonucleotides of reduced toxicity Download PDF

Info

Publication number
WO2002036767A3
WO2002036767A3 PCT/CA2001/001540 CA0101540W WO0236767A3 WO 2002036767 A3 WO2002036767 A3 WO 2002036767A3 CA 0101540 W CA0101540 W CA 0101540W WO 0236767 A3 WO0236767 A3 WO 0236767A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
therapeutic oligonucleotide
oligonucleotides
aggregates
reduced toxicity
Prior art date
Application number
PCT/CA2001/001540
Other languages
French (fr)
Other versions
WO2002036767A2 (en
Inventor
Thomas D Madden
Murray S Webb
Original Assignee
Inex Pharmaceuticals Corp
Thomas D Madden
Murray S Webb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inex Pharmaceuticals Corp, Thomas D Madden, Murray S Webb filed Critical Inex Pharmaceuticals Corp
Priority to EP01983356A priority Critical patent/EP1330520A2/en
Priority to CA002426047A priority patent/CA2426047A1/en
Priority to AU2002214868A priority patent/AU2002214868A1/en
Priority to JP2002539513A priority patent/JP2004512383A/en
Publication of WO2002036767A2 publication Critical patent/WO2002036767A2/en
Publication of WO2002036767A3 publication Critical patent/WO2002036767A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates

Abstract

It has now been discovered that oligonucleotides which tend to form multimeric aggregates have greater toxicity in the aggregate form than in monomeric form. Thus, the present invention provides therapeutic oligonucleotide compositions of reduced in vivo toxicity, and a method for making such compositions, as well as a method for administration of the therapeutic oligonucleotide, where the therapeutic oligonucleotide in one that tends to form multimeric aggregates. Compositions containing such aggregate-forming oligonucleotides are treated by heating, preferably no more than 24 hours prior to administration, or using chemical species such as mannitol which disrupt aggregates.
PCT/CA2001/001540 2000-11-02 2001-10-31 Therapeutic oligonucleotides of reduced toxicity WO2002036767A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP01983356A EP1330520A2 (en) 2000-11-02 2001-10-31 Therapeutic oligonucleotides of reduced toxicity
CA002426047A CA2426047A1 (en) 2000-11-02 2001-10-31 Therapeutic oligonucleotides of reduced toxicity
AU2002214868A AU2002214868A1 (en) 2000-11-02 2001-10-31 Therapeutic oligonucleotides of reduced toxicity
JP2002539513A JP2004512383A (en) 2000-11-02 2001-10-31 Therapeutic oligonucleotides with reduced toxicity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24517600P 2000-11-02 2000-11-02
US60/245,176 2000-11-02

Publications (2)

Publication Number Publication Date
WO2002036767A2 WO2002036767A2 (en) 2002-05-10
WO2002036767A3 true WO2002036767A3 (en) 2003-01-23

Family

ID=22925600

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2001/001540 WO2002036767A2 (en) 2000-11-02 2001-10-31 Therapeutic oligonucleotides of reduced toxicity

Country Status (5)

Country Link
EP (1) EP1330520A2 (en)
JP (1) JP2004512383A (en)
AU (1) AU2002214868A1 (en)
CA (1) CA2426047A1 (en)
WO (1) WO2002036767A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7956043B2 (en) 2002-12-11 2011-06-07 Coley Pharmaceutical Group, Inc. 5′ CpG nucleic acids and methods of use
US8258106B2 (en) 1994-07-15 2012-09-04 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US8574599B1 (en) 1998-05-22 2013-11-05 Ottawa Hospital Research Institute Methods and products for inducing mucosal immunity

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ616745A (en) * 2008-07-18 2014-06-27 Oncogenex Tech Inc Antisense formulation
WO2010062697A2 (en) 2008-10-30 2010-06-03 Peixuan Guo Membrane-integrated viral dna-packaging motor protein connector biosensor for dna sequencing and other uses
WO2023282344A1 (en) * 2021-07-08 2023-01-12 日本新薬株式会社 Nephrotoxicity reducing agent
TW202337473A (en) * 2021-07-08 2023-10-01 日商日本新藥股份有限公司 Nephrotoxicity-reducing agent
CA3225573A1 (en) * 2021-07-08 2023-01-12 Nippon Shinyaku Co., Ltd. Precipitation suppressing agent

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997006827A1 (en) * 1995-08-14 1997-02-27 Icn Pharmaceuticals Control of cd44 gene expression for therapeutic use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997006827A1 (en) * 1995-08-14 1997-02-27 Icn Pharmaceuticals Control of cd44 gene expression for therapeutic use

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8258106B2 (en) 1994-07-15 2012-09-04 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US8574599B1 (en) 1998-05-22 2013-11-05 Ottawa Hospital Research Institute Methods and products for inducing mucosal immunity
US7956043B2 (en) 2002-12-11 2011-06-07 Coley Pharmaceutical Group, Inc. 5′ CpG nucleic acids and methods of use

Also Published As

Publication number Publication date
EP1330520A2 (en) 2003-07-30
CA2426047A1 (en) 2002-05-10
AU2002214868A1 (en) 2002-05-15
JP2004512383A (en) 2004-04-22
WO2002036767A2 (en) 2002-05-10

Similar Documents

Publication Publication Date Title
WO2003013437A3 (en) Compositions and methods for the prevention and treatment of huntington's disease
WO2005049630A3 (en) Antisense modulation of kinesin-like 1 expression
WO2004100881A3 (en) Preparation and use of aryl alkyl acid derivatives for the treatment of obesity
DE60207744D1 (en) PROCESS FOR THE PREPARATION OF 1,5,6,7-TETRAHYDROPYRROLO [3,2-C] DERIVATIVES FOR THE TREATMENT OF FATIBILITY
WO2003011887A3 (en) Antisense modulation of apolipoprotein b expression
EP1478322A4 (en) Beta-2'-OR 3'-HALONUCLEOSIDES
HK1048990A1 (en) Novel compounds.
ZA979961B (en) 5-HT1F agonists
WO2003070283A3 (en) Agent for inhibiting development or progress of proliferative diseases and especially cancer diseases and pharmaceutical composition containing said agent
TW200633986A (en) Therapeutic agents
WO2001032832A3 (en) Antisense inhibition of nucleolin expression
WO2002036767A3 (en) Therapeutic oligonucleotides of reduced toxicity
WO2009027978A8 (en) NUCLEIC ACID SEQUENCES COMPRISING NF-ϰB BINDING SITE WITHIN O(6)-METHYLGUANINE-DNA-METHYLTRANSFERASE (MGMT) PROMOTER REGION AND USES THEREOF FOR THE TREATMENT OF CANCER AND IMMUNE-RELATED DISORDERS
WO2004073375A8 (en) Podophyllotoxin derivatives as antitumor agents
WO2006066154A3 (en) Casein kinase 2 antisense therapy
WO2003050244A3 (en) Antisense modulation of g protein-coupled receptor etbr-lp-2 expression
EP1248633A4 (en) Antisense modulation of glycogen synthase kinase 3 beta expression
EP0916670A3 (en) Pyrrolo-(3,2-b) pyridines and their use as 5-HT1F agonists
WO2003030826A3 (en) Antisense modulation of insulin-like growth factor binding protein 5 expression
WO2003099224A3 (en) Antisense moodulation of kinesin-like 1 expression
WO2003057847A3 (en) METHODS AND MATERIALS FOR MODULATING ENaC-BETA
WO2005039480A8 (en) AChE ANTISENSE DEOXYOLIGONUCLEOTIDE AS AN ANTI-INFLAMMATORY AGENT
MXPA05009428A (en) Compositions and methods for preventing and treating endotoxin-related diseases and conditions.
EP1173458A4 (en) Antisense modulation of sra expression
EP1448762A4 (en) Antisense modulation of toll-like receptor 4 expression field of the invention

Legal Events

Date Code Title Description
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2426047

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002539513

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001983356

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001983356

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001983356

Country of ref document: EP